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complications.
Review of themedical records revealed that in 9 of
the patient’s complete blood counts over the previ-
ous 2 years, the laboratory had commented that the
patient’s blood sample ‘‘required rewarming’’ and
appeared ‘‘markedly agglutinated.’’ Laboratory re-
sults from the previous year showed a progressive
decrease in hemoglobin and gradual increases in
lactate dehydrogenase and mean corpuscular vol-
ume, indicating progression of CAD. An increase in
the CD4-to-CD8 ratio was also observed, indicating
simultaneous progression of SS. These findings sug-
gest that the patient may have had pathologic CAs
causing low-grade hemolysis and agglutination for 2
years while undergoing ECP.
The incidence of CAD is 1 per million per year,
and the disease is divided into primary and second-
ary subtypes.1 Primary CAD is monoclonal, chronic,
and associated with lymphoproliferative malig-
nancies, most frequently CLL. Secondary CAD is
transient, polyclonal, and associated with viral and
mycoplasma infections.1 CAs are found at low levels
in the sera of most healthy individuals and react at
low temperatures. They may become pathologic at
high titers or high thermal amplitudes, the temper-
ature at which the autoantibodies react.1-4 Activation
of CAseprecipitated by exposure to low tempera-
tures and acute phase reactantsecan result in cold-
induced circulatory symptoms such as acrocyanosis,
as well as catastrophic hemagglutination and hemo-
lysis.1,2 Clues to the diagnosis of CAD in our patient
include chronic macrocytic anemia, a history of CLL,
and temperature-dependent hemagglutination.1-5
Although his CAD and SS were progressing simulta-
neously, there are no reports of a correlation be-
tween the 2 conditions. We attribute the patient’s
CAD to his underlying CLL. Hemagglutination may
have been precipitated by his recent viral illness and
environmental conditions during ECP. We have
presented a potentially serious complication that
occurred during the use of a therapy that is broadly
applied by multiple medical specialties. Awareness
of the risk factors, signs, and symptoms of CAD, and
appropriate pretreatment screening may help avoid
this rare but significant adverse event in patients with
CAs undergoing ECP.
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concomitant anti-MDA5 features
To the Editor:Dermatomyositis (DM) is amultisystem
autoimmune disease for which multiple phenotypes
have been described. Here we report the case of a
patient with both Wong-type DM and features of a
DM phenotype associated with anti-melanoma
differentiation-associated gene 5 antibodies (anti-
MDA5 DM).
A previously healthy 54-year-old man presented
with a 1-year history of a progressive eruption
previously diagnosed as pityriasis rubra pilaris
(PRP) by 2 independent dermatologists. He had
failed topical corticosteroids and 2 courses of oral
prednisone pulses, and subsequently weakness and
dyspnea on exertion developed. His past medical
history was unremarkable.
Exam revealed confluent pink-orange patches
and plaques over the trunk with islands of sparing
(Fig 1), and his extremities displayed hyperkeratotic
follicular papules. He also had painful violaceous
palmar papules (Fig 2), ragged cuticles, rough radial
palms and digits, and subtle violaceous periorbital
edema. Proximal muscle strength was 4-51.
Fig 1. Wong-type dermatomyositis. Widespread confluent
salmon pink/orange colored patches and scaly plaques
with well defined islands of sparing over the trunk.
Fig 2. MDA5dermatomyositis. Multiple violaceous palmar
and digital papules and rough radial palms and digits.
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lymphocytes and rare eosinophils below a thin
epidermis with vacuolar interface change and
necrotic keratinocytes. There was increased mucin
in the superficial reticular dermis and hyperkeratosis
over follicular infundibulum.
A mild elevation of creatine kinase (CK) and
inflammatory markers were noted. Results were
positive for antinuclear antibodies (speckledpattern) and negative for antibodies to Jo1, SSA,
and SSB. Electromyography (EMG) and muscle
biopsy were consistent with DM. High-resolution
chest computed tomography and an age-appropriate
malignancy work-up were unremarkable.
Taken together, his mixed DM and PRP-like pre-
sentation, histopathology, EMG, muscle biopsy, and
CK elevation were consistent with Wong-type DM.
His distinct painful palmar papules raised concern
for the anti-MDA5 antibody positive DM subtype.
Subsequent enzyme-linked immunosorbent assay
for anti-MDA5 was positive. He was treated with
intravenousmethylprednisolone (subsequently tran-
sitioned to a slow prednisone taper), intravenous
immunoglobulin, mycophenolic mofetil, and hy-
droxychloroquine. He experienced rapid recovery
and demonstrated only minimal cutaneous symp-
toms and no internal manifestations after 10 months.
Wong-type DM is an exceedingly rare DM subtype
characterized by PRP-like morphology,1 which has
been described in all 22 prior cases.2 Histologic
findings vary,with features ranging from those typical
of DMor PRP alone, to a combination of both (as seen
in our patient). Hyperkeratosis overlying follicular
infundibulum, as reported here, is common.2
Similar to typical DM, Wong-type appears to carry
a risk for myositis and interstitial lung disease (ILD).
Unlike other subtypes, Wong-type DM is not associ-
ated with internal malignancy.2 Our patient’s malig-
nancy work-up was negative.
Anti-MDA5 DM is a recently described unique DM
phenotype with a number of distinct morphologic
features, with painful palmar papules and mucocu-
taneous ulcerations being among the most charac-
teristic.3 Incidence ranges from 10% to 20% in Japan
to 7% to 13% in the United States.3-5 Our patient both
displayed many anti-MDA5 features, including pain-
ful violaceous palmar papules, and had a positive
anti-MDA5 ELISA.
The most important consequence of anti-MDA5
DM is an increased risk for rapidly progressive ILD
and resultant decreased survival, relative to other
subtypes.3,4 Therefore some recommend early and
aggressive treatment in suspected cases of anti-
MDA5 DM.4 Of note, internal malignancy appears
to be less common in anti-MDA5 DM. Fortunately,
our patient had neither ILD nor malignancy.
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Fig 1. Dermatomyositis. Erythematous papules overlying
the metacarpal and interphalangeal joints (Gottron
papules).
Fig 2. Dermatomyositis. Hematoxylin and eosin stain of
dorsal hand punch biopsy. Vacuolar interface dermatitis
with sparse perivascular inflammation.
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Dermatomyositis associated with antietumor
necrosis factor therapy in a patient with
psoriasis
To the Editor: Antietumor necrosis factor (a-TNF)
agents have become a common treatment for many
different autoimmune diseases. Due to conflicting
effects mediated by TNF, a-TNF therapies both
treat and induce autoimmune disease. Herein we
discuss a novel case of a-TNFeinduced amyopathic
dermatomyositis (DM) in a patient with a history of
psoriasis.
A 37-year-old Brazilian woman was referred to
our medical center for management of psoriasis. She
had a 7-year history of biopsy-proven psoriatic
plaques that had failed topical therapies and were
exacerbated by UV therapy. Physical exam revealed
a large 20- 3 30-cm erythematous, scaly plaque on
her back, and more than 20 guttate papules on her
elbows and extensor forearms. She was started on
adalimumab 40 mg biweekly following routine lab
work and a negative tuberculosis test.
One month later, her psoriasiform plaques
had markedly improved, but indurated violaceous
plaques overlying her knuckles with ragged cuticles
and looped telangiectasias developed (Fig 1).
Because she was satisfied with the resolving
psoriasis, adalimumab was continued.A biopsy specimen from the periarticular dorsal
hand skin papule was obtained (Fig 2).
Biopsy revealed an atrophic epidermis and subtle
vacuolar interface change associated with sparse
superficial perivascular inflammation with increased
dermal mucin. She denied myalgias or muscle
weakness. Laboratory findings revealed a negative
ANA, negative SCL70, a creatine kinase of 136 U/L,
and a jo-1 \ 1. Based on the clinical, laboratory,
and pathologic findings, the diagnosis of DM
was made. The patient has had negative results
on age-appropriate cancer screenings, including
gynecologic exam, computed tomography of
abdomen/pelvis, and chest roentgenogram, as well
as normal pulmonary function tests. Over the
subsequent 10 months, she has had no other
manifestations of DM. Her Gottron papules have
softened somewhat with the addition of metho-
trexate. To our knowledge, anti-TNFeinduced DM
has not been previously reported in a patient with
psoriasis.
Vasculitis, psoriaform eruptions, and a lupus-like
syndrome are the most common a-TNFeinduced
